Together with our findings, this suggests that small node negative HER2+ tumours have a good prognosis if they are ER+, and hence that the benefits of adding chemotherapy and HER2-targeted therapy on top of endocrine therapy may not be substantial. The gene discussed is ERBB2; the disease is neoplasm.